Vaxart (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving Average of $0.88

Vaxart, Inc. (NASDAQ:VXRT)’s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.88 and traded as low as $0.86. Vaxart shares last traded at $0.87, with a volume of 1,069,507 shares changing hands.

Wall Street Analyst Weigh In

Separately, B. Riley upgraded shares of Vaxart from a “neutral” rating to a “buy” rating and set a $2.00 target price for the company in a report on Wednesday, January 31st.

Vaxart Trading Down 10.3 %

The stock has a market cap of $131.37 million, a price-to-earnings ratio of -1.30 and a beta of 0.44. The stock’s 50 day moving average is $1.16 and its two-hundred day moving average is $0.88.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. The firm had revenue of $3.25 million during the quarter, compared to analysts’ expectations of $0.45 million. Vaxart had a negative net margin of 1,117.56% and a negative return on equity of 108.45%. On average, sell-side analysts predict that Vaxart, Inc. will post -0.45 EPS for the current year.

Institutional Trading of Vaxart

Several hedge funds have recently made changes to their positions in the company. Kingswood Wealth Advisors LLC acquired a new stake in shares of Vaxart in the 1st quarter worth $32,000. Vanguard Group Inc. lifted its stake in shares of Vaxart by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 7,044,971 shares of the biotechnology company’s stock worth $4,035,000 after acquiring an additional 88,131 shares during the period. Virtu Financial LLC purchased a new position in shares of Vaxart in the 4th quarter valued at about $25,000. GSA Capital Partners LLP increased its holdings in shares of Vaxart by 72.7% in the 4th quarter. GSA Capital Partners LLP now owns 488,496 shares of the biotechnology company’s stock valued at $280,000 after purchasing an additional 205,559 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Vaxart by 25.8% in the fourth quarter. Northern Trust Corp now owns 334,135 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 68,441 shares during the period. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia.